Akebia Therapeutics launches AkebiaCares, an enhanced patient access program fo CKD
Akebia Therapeutics announced the launch of AkebiaCares, its enhanced patient access program. Auryxia is the only oral iron tablet approved in the U.S. to treat non-dialysis-dependent-chronic kidney disease adult patients for IDA, and dialysis-dependent CKD adult patients for hyperphosphatemia. June 11, 2019